1.Synthesis and antitumor activity of fluoroquinolon-3-yl-s-triazole sulfide ketones and their derivatives from ciprofloxacin.
Li-li NI ; Qiang YAN ; Shu-min WU ; Yu-suo XIE ; Liu-zhou GAO ; Ying-jie LIU ; Wen-long HUANG ; Guo-qiang HU
Acta Pharmaceutica Sinica 2015;50(10):1258-1262
To discover an efficient strategy for the conversion of the antibacterial activity of fluoroquinolones into the antitumor activity, the three series of C-3 s-triazole-based derivatives including sulfide ketones (6a-6g), thiosemicarbazones (7a-7g) and fused heterocyclic thiazolotriazoles (8a-8g) were synthesized from ciprofloxacin (1), respectively. The structures were characterized by elemental analysis and spectral data. The antitumor activity was tested against three tumor cell lines (Hep-3B, Capan-1 and HL60) using the MTT assay. The three types of compounds all exhibited stronger anti-proliferative activities than ciprofloxacin in the test. The order of their activities was in compounds 7>8>6, and the order of selectivity against cancer cell lines was Capan-1, Hep-3B and HL60. Meanwhile, the SAR revealed that some compounds with electron-drawing group substituted such as fluoro- and nitro-phenyl compounds (6f, 7f, 8f) and (6g, 7g, 8g) displayed more significant activity than the control compounds, especially the IC50 values of thiosemicarbazone compounds 7f and 7g against Capan-1 was comparable to doxorubicin. Thus, a five-membered triazole as the C-3 bioisostere modified with the functionalized side-chain of sulfide-ketone thiosemicarbazone warrants special attention and further investigation.
Anti-Bacterial Agents
;
chemistry
;
Antineoplastic Agents
;
pharmacology
;
Cell Line, Tumor
;
Ciprofloxacin
;
chemistry
;
Doxorubicin
;
pharmacology
;
HL-60 Cells
;
Humans
;
Ketones
;
pharmacology
;
Sulfides
;
pharmacology
;
Triazoles
;
pharmacology
2.Accumulation of ciprofloxacin and lomefloxacinin fluoroquinolone-resistant strains of Escherichia coli.
Peiyuan XIA ; Ping FENG ; Li ZHONG ; Xiaojü LU ; Bingjün LEI
Chinese Medical Journal 2002;115(1):31-35
OBJECTIVETo evaluate the role of outer membrane protein (Omp) F-deficiency and active efflux in the accumulation of hydrophilic fluoroquinolones ciprofloxacin (CPLX) and lomefloxacin (LMLX) in resistant E. coli strains.
METHODSFluoroquinolone accumulation in bacteria and the effect of active efflux were measured by a fluorescence method. The outer membrane proteins of the bacteria were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). E. coli strains in this study included control strains JF701 and JF703 that are OmpC- or OmpF-deficient mutants of E. coli K-12, respectively, and the fluoroquinolone susceptible strain the fluoroquinolone susceptible strain of Escherichia coli (Ecs) and its in vitroselected resistant strains R2 and R256, and the clinical resistant isolates R5 and R6.
RESULTSThe steady-state accumulation concentration of each drug in Ecs appeared to be the same as in JF701, while in the OmpF-deficient strain JF703, it was 1/5 CPLX or 1/2 LMLX lower than that in JF701, but JF703 was still susceptible to fluoroquinolones. On the other hand, compared with susceptible strains, a 2- to 10-fold decrease in the accumulation of each drug was found in the resistant strains except R2, in which the accumulation was slightly higher than in JF703. After the addition of 2,4-dinitrophenol (DNP), accumulation of each drug increased, especially in resistant strains, indicating that the function of the active efflux (pump) system in these bacteria had been enhanced dramatically. Furthermore, both OmpF and OmpC in Ecs, OmpF-deficiency in R2 and R256 and OmpC-deficiency in R5 and R6 were observed.
CONCLUSIONThe decreased accumulation of hydrophilic fluoroquinolones in E. coli involved OmpF-deficiency and active efflux (pump), and the latter may be an important factor.
2,4-Dinitrophenol ; pharmacology ; Anti-Infective Agents ; metabolism ; pharmacology ; Ciprofloxacin ; metabolism ; pharmacology ; Drug Resistance, Bacterial ; Escherichia coli ; drug effects ; metabolism ; Fluoroquinolones ; Porins ; physiology ; Quinolones ; metabolism ; pharmacology
3.Synthesis and anti-proliferative activity of fluoroquinolone C-3 fused heterocyclic α,β-unsaturated ketones derived from ciprofloxacin.
Taol LI ; Zhou Gao LIU ; Yu-suo XIE ; Yan-fei FENG ; Qiang YAN ; Shu-min WU ; Li-li NI ; Hui ZHAO ; Wen-long HUANG ; Guo-qiang HU
Acta Pharmaceutica Sinica 2015;50(5):569-573
To discover novel antitumor fluoroquinolone lead compounds from a rational modification for antibacterial fluoroquinolones, a fused heterocyclic ketone corresponding to thiazolo[2,3- b][1,2,4]triazolone used as a bioisosteric replacement of the C-3 carboxylic acid group of ciprofloxacin 1, and further modification by a Claisen condensation reaction with substituted benzaldehydes formed novel fluoroquinolone C-3 fuse heterocyclic α, β-unsaturated ketones as the title compounds (6a-6r), separately. The structures of eighteen title compounds were characterized by elemental analysis, 1H NMR and MS, and the in vitro anti-proliferative activity against human hepatoma Hep-3B cells, pancreatic Capan-1 cells and leukemia HL60 cells was evaluated by a MTT assay. The preliminary results showed that the title compounds not only had more significant anti-proliferative activity against three tested cancer cell lines than that of the parent ciprofloxacin 1, but also exhibited the highest activity against Capan-1 cells. In particular, compounds carrying an electron-withdrawing carboxyl (6k, 6m) or sulfonamide substituent (6q, 6r) attached to benzene ring were comparable to or better than constractive drug doxorubicin against Capan-1 cells. As such, it suggests that it is favorable for a fused heterocyclic α, β-unsaturated ketone scaffold instead of the C-3 carboxylic acid group to improve the antitumor activity of fluoroquinolones.
Anti-Bacterial Agents
;
Antineoplastic Agents
;
chemical synthesis
;
pharmacology
;
Cell Line, Tumor
;
Ciprofloxacin
;
analogs & derivatives
;
Fluoroquinolones
;
chemical synthesis
;
pharmacology
;
HL-60 Cells
;
Humans
;
Ketones
;
pharmacology
;
Structure-Activity Relationship
4.Activity of ciprofloxacin and azithromycin on biofilms produced in vitro by Haemophilus influenzae.
Dong WANG ; Ying WANG ; You-ning LIU
Chinese Medical Journal 2009;122(11):1305-1310
BACKGROUNDIt is recognized that Haemophilus influenzae isolated from patients with otitis media forms biofilms both in vitro and in vivo, suggesting that biofilm formation in vivo might play an important role in the pathogenesis and chronicity of otitis media, but the effect of antibiotics on biofilm has not been well studied. We investigated the impact of ciprofloxacin and azithromycin on bacterial biofilms formed by Haemophilus influenzae in vitro in this study.
METHODSEleven strains of Haemophilus influenzae were isolated from sputum specimens collected from patients with acute exacerbation of chronic obstructive pulmonary diseases. Formation of bacterial biofilm was examined by crystal violet assay and a scanning electron microscope. Alterations of biofilms were measured under varying concentrations of azithromycin and ciprofloxacin.
RESULTSStriking differences were observed among strains with regard to the ability to form biofilm. Typical membrane-like structure formed by bacterial cells and extracellular matrix was detected. Initial biofilm synthesis was inhibited by azithromycin and ciprofloxacin at concentrations higher than two-fold minimal inhibitory concentration. Disruption of mature biofilms could be achieved at relatively higher concentration, and ciprofloxacin displayed more powerful activity.
CONCLUSIONSHaemophilus influenzae is capable of forming biofilm in vitro. Sufficient dosage might control early formation of biofilms. Ciprofloxacin exerts better effects on breakdown of biofilm than azithromycin at conventional concentration in clinics.
Anti-Bacterial Agents ; pharmacology ; Azithromycin ; pharmacology ; Biofilms ; drug effects ; Ciprofloxacin ; pharmacology ; Haemophilus influenzae ; drug effects ; isolation & purification ; Humans ; Lung Diseases, Obstructive ; microbiology ; Microbial Sensitivity Tests ; Microscopy, Electron, Scanning
5.In-Vitro Efficacy of Synergistic Antibiotic Combinations in Multidrug Resistant Pseudomonas Aeruginosa Strains.
Yonsei Medical Journal 2010;51(1):111-116
PURPOSE: Combination antibiotic treatment is preferred in nosocomial infections caused by Pseudomonas aeruginosa (P. aeruginosa). In vitro synergism tests were used to choose the combinations which might be used in clinic. The aim of this study was to investigate the synergistic efficacy of synergistic antibiotic combinations in multidrug resistant P. aeruginosa strains. MATERIALS AND METHODS: Synergistic efficacies of ceftazidime-tobramycin, piperacillin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-isepamycin, imipenem-ciprofloxacin and ciprofloxacin-tobramycin combinations were investigated by checkerboard technique in 12 multiple-resistant and 13 susceptible P. aeruginosa strains. RESULTS: The ratios of synergy were observed in ceftazidime-tobramycin and piperacillin/tazobactam-tobramycin combinations as 67%, and 50%, respectively, in resistant strains, whereas synergy was not detected in other combinations. The ratios of synergy were observed in ceftazidime-tobramycin, piperacillin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-ciprofloxacin and imipenem-isepamycin combinations as 31%, 46%, 15%, 8%, 8%, and respectively, in susceptible strains, whereas synergy was not detected in ciprofloxacin-tobramycin combination. Antagonism was not observed in any of the combinations. CONCLUSION: Although the synergistic ratios were high in combinations with ceftazidime or piperacillin/tazobactam and tobramycin, the concentrations in these combinations could not usually reach clinically available levels. Thus, the solution of the problems caused by multiple resistant P. aeruginosa should be based on the prevention of the development of resistance and spread of the causative agent between patients.
Anti-Bacterial Agents/*pharmacology
;
Ceftazidime/pharmacology
;
Ciprofloxacin/pharmacology
;
Drug Resistance, Multiple, Bacterial/*drug effects
;
Drug Synergism
;
Imipenem/pharmacology
;
Microbial Sensitivity Tests
;
Penicillanic Acid/analogs & derivatives/pharmacology
;
Piperacillin/pharmacology
;
Pseudomonas aeruginosa/*drug effects
;
Tobramycin/pharmacology
6.Antimicrobial Susceptibility Patterns of Legionella isolates in the Environment and in Patients.
Go Eun CHOI ; Jeong Eun KANG ; Eun Yup LEE ; Chulhun L CHANG ; Kazuhiro TATEDA ; Keizo YAMAGUCHI ; Kyeong Hee KIM ; Jeong Man KIM
The Korean Journal of Laboratory Medicine 2010;30(1):28-33
BACKGROUND: Antimicrobial susceptibility of Legionella spp. has rarely been studied in Korea. Therefore, we aimed to determine the susceptibility of Legionella spp. to various antibiotics. METHODS: We assessed the antimicrobial susceptibility of 66 environmental and clinical Legionella isolates collected between January 2001 and December 2008 from Korea and Japan. The minimum inhibitory concentrations (MICs) of 6 antibiotics, namely, azithromycin, ciprofloxacin, clarithromycin, clindamycin, gatifloxacin, and gemifloxacin were determined by the broth microdilution method using buffered starch yeast extract broth. RESULTS: The MIC ranges of the 6 antibiotics used against the Legionella isolates were as follows: 0.004-0.062 microgram/mL (azithromycin), 0.002-0.5 microgram/mL (ciprofloxacin), 0.004-0.5 microgram/mL (clarithromycin), 0.12-4 microgram/mL (clindamycin), 0.002-0.12 microgram/mL (gatifloxacin), and 0.008-1 microgram/mL (gemifloxacin). CONCLUSIONS: Legionella spp. isolates from Korea and Japan were most susceptible to gatifloxacin. Azithromycin, clarithromycin, ciprofloxacin, and gemifloxacin were also effective for treating legionellosis.
Anti-Bacterial Agents/*pharmacology
;
Azithromycin/pharmacology
;
Ciprofloxacin/pharmacology
;
Clarithromycin/pharmacology
;
Clindamycin/pharmacology
;
Drug Resistance, Bacterial
;
Fluoroquinolones/pharmacology
;
Humans
;
Legionella/*drug effects/isolation & purification
;
Legionellosis/diagnosis/microbiology
;
Microbial Sensitivity Tests
;
Naphthyridines/pharmacology
7.Clinical isolates of Mycobacterium abscessus in Guangzhou area most possibly from the environmental infection showed variable susceptibility.
Feng-Lin ZHUO ; Zhao-Gang SUN ; Chuan-You LI ; Zhi-Hui LIU ; Lin CAI ; Cheng ZHOU ; Jian-Zhong ZHANG
Chinese Medical Journal 2013;126(10):1878-1883
BACKGROUNDMycobacterium abscessus (M. abscessus) can cause a variety of human infections, involving the lung, skin and soft tissues, and is generally believed to be acquired from environmental sources. The aim of this study was to investigate the molecular diversity and antibiotic susceptibility of M. abscessus isolates as the basis for strategies to improve control and management of infection.
METHODSSeventy M. abscessus isolates from patients attending the Guangzhou Thoracic Hospital were identified from 2003 to 2005 by biochemical tests, gas chromatography, polymerase chain reaction (PCR)-restriction analysis (PRA) of heat shock protein gene hsp65, and sequencing of the quinolone resistance determining regions (QRDRs) of gyrA. Susceptibilities to six antibiotics were determined by micro-broth dilution. Isolates were genotyped using randomly amplified polymorphic DNA (RAPD) analysis.
RESULTSMost isolates (63/70; 90%) were susceptible to amikacin but rates of susceptibility to other antibiotics varied from moderate, clarithromycin (60%) and imipenem (43%), to low for ciprofloxacin and ofloxacin (3%), and 87% of isolates had intermediate susceptibility to cefoxitin. RAPD analysis showed that the 70 clinical isolates displayed 69 unique RAPD patterns.
CONCLUSIONSThe high genetic diversity of isolates suggests that they are not transmitted from person to person but, presumably, are acquired independently from environmental sources. M. abscessus isolates displayed variable levels of susceptibility to all antibiotics tested, other than amikacin, indicating a need for routine susceptibility testing to guide treatment.
Amikacin ; pharmacology ; Anti-Bacterial Agents ; pharmacology ; Cefoxitin ; pharmacology ; China ; Chromatography, Gas ; Ciprofloxacin ; pharmacology ; Clarithromycin ; pharmacology ; Imipenem ; pharmacology ; Microbial Sensitivity Tests ; Mycobacterium ; drug effects ; genetics ; Polymerase Chain Reaction ; Random Amplified Polymorphic DNA Technique
8.Synthesis and in vitro antibacterial activities of new 3,5-disubstituted oxazolidinone compounds.
Qing-guo MENG ; Qi WANG ; Jun LIU
Acta Pharmaceutica Sinica 2003;38(10):754-759
AIMTo design and synthesize new oxazolidinone antibacterial agents.
METHODSThe synthetic method reported in literature has been modified and new 3,5-disubstituted oxazolidinone compounds were synthesized on the basis of SAR reported in the literature and their antibacterial activities in vitro were determined.
RESULTSEighteen new objective compounds were synthesized, and their structures were determined by IR, 1HNMR and FAB-MS. Within the eighteen new objective compounds, sixteen compounds showed antibacterial activity in vitro and compound 9, 10 and 10b showed better antibacterial activities in vitro than ciprofloxacin (CIP), sultamicillin (Sul) and vancomycin (VCO). Compounds 9a and 11c have no antibacterial activity in vitro at all.
CONCLUSIONCompounds 9, 10 and 10b are worthy to be intensively studied.
Ampicillin ; pharmacology ; Anti-Bacterial Agents ; chemical synthesis ; chemistry ; pharmacology ; Ciprofloxacin ; pharmacology ; Microbial Sensitivity Tests ; Molecular Structure ; Oxazolidinones ; chemical synthesis ; chemistry ; pharmacology ; Staphylococcus aureus ; drug effects ; Streptococcus ; drug effects ; Structure-Activity Relationship ; Sulbactam ; pharmacology ; Vancomycin ; pharmacology
9.Release of DNA from Pseudomonas aeruginosa in vitro during spontaneous growth and treatment with ciprofloxacin.
Dai-Zhi PENG ; Charles H GUYMON ; Albert T MCMANUS ; Guang-Xia XIAO
Chinese Journal of Surgery 2005;43(3):178-181
OBJECTIVETo observe the DNA release from Pseudomonas aeruginosa (P. aeruginosa) during spontaneous growth and exposure to different concentrations of ciprofloxacin (Cipro) in vitro.
METHODSThe P. aeruginosa 1244 strain (ATCC 27317) was selected because it was sensitive to Cipro in vitro. The minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of Cipro against this strain were determined, respectively. Different concentrations of Cipro were cultured with this strain at 37 degrees C for 4 h and 24 h. The samples of culture supernatant were filtered and electrophoresed in 1.8% agarose with SYBR Gold stain. Then the images of the gel sheets were photographed.
RESULTSThe MIC and MBC of Cipro were 0.25 - 0.5 mg/L. The free bacterial DNA in 4 h culture samples with or without Cipro could not be detected by this method. The certain amount of free bacterial DNA molecules in 24 h culture samples without antibiotic appeared at the two zones whose molecular weights were more than 2000 bp and less than 100 bp. The large amount of free bacterial DNA molecules showed at three zones in 24 h culture samples with Cipro when its concentrations were much lower than its MIC. In terms of DNA molecular weight, the first two zones were above 2000 bp, and the third zone was below 100 bp. There was no detectable DNA release from bacteria in 24 h culture samples when Cipro was at or above its MIC.
CONCLUSIONSThe certain amount of bacterial DNA were released from P. aeruginosa in the spontaneous growth. Different concentrations of Cipro had quite differential effects on the DNA release from P. aeruginosa in quantities and molecular weights in vitro.
Anti-Infective Agents ; administration & dosage ; pharmacology ; Ciprofloxacin ; administration & dosage ; pharmacology ; DNA, Bacterial ; metabolism ; Dose-Response Relationship, Drug ; In Vitro Techniques ; Microbial Sensitivity Tests ; Pseudomonas aeruginosa ; drug effects ; metabolism
10.The action of Pseudomonas aeruginosa biofilms in intrinsic drug resistance.
Yi XIE ; Wen-xiang JIA ; Wei ZENG ; Wei-qing YANG ; Xi CHENG ; Xue-ru LI ; Lan-lan WANG ; Mei KANG ; Zai-rong ZHANG
Chinese Medical Journal 2005;118(19):1615-1622
BACKGROUNDThere is a growing interest in studying the relationship between intrinsic resistance and biofilms resistance to drugs. However, the relationship still remains unclear in the macroscopic bacterial growth. Our study is to illuminate the change of bacterial drug resistance of gyrA mutant and active efflux pump during the development of Pseudomonas aeruginosa (P. aeruginosa) biofilms.
METHODSThe strains of type II topoisomerase gene mutant (gyrA mutant) and multidrug resistance (MDR) efflux pump were clinical isolates and detected by polymerase chain reaction (PCR). The process of bacterial biofilms development was observed by scanning electron microscope. Triparental mating experiments were performed to transfer report gene of green fluorescent protein (GFP) into P. aeruginosa biofilms strains and followed by analysis of bacterial survival rate between intrinsic resistance and biofilms resistance.
RESULTSThe fluorescent strains with pGFPuv could develop mature biofilms on Teflon surface. Before a period of 72 hours, the survival rate of biofilms bacteria and intrinsic resistance strains in ciprofloxacin solution was significantly different (P < 0.05). The survival number of intrinsic resistance strains (gyrA mutation and active efflux pump) was illustriously higher than biofilm strain in the initial stage of biofilms development. After 72 hours incubation, there was no clearly difference between mutants and biofilms strains in the survival rate (P > 0.05). The carbonyl cyanide m-chlorophenylhydrazone and azithromycin could significantly reduce the drug resistance of biofilm strains and efflux pump strains.
CONCLUSIONSIn the development of P. aeruginosa biofilms, the strains of gyrA mutation and MDR efflux could be conferred with new level of drug resistance. When co-cultured mutated strains with biofilm strains, biofilms may play a major role in bacterial resistance. But after 72 hours incubation (a mature biofilms had been developed), there was no clearly difference between the number of mutant strains and biofilm strains.
Biofilms ; drug effects ; Carbonyl Cyanide m-Chlorophenyl Hydrazone ; pharmacology ; Ciprofloxacin ; pharmacology ; DNA Gyrase ; genetics ; Drug Resistance, Bacterial ; Mutation ; Pseudomonas aeruginosa ; drug effects ; genetics